automated health care

Houston hospital system celebrates revolutionary robotic-assisted heart surgery

Another HCA Houston hospital hit a major milestone in robotics-assisted surgery. Photo courtesy of HCA

HCA Houston Healthcare Medical Center has successfully completed a robotic-assisted coronary angioplasty — the first of its kind, the hospital reports.

Dr. Pranav Loyalka, cardiologist with Houston Heart, completed the procedure using the first and only FDA-cleared robotic-assisted technology. The process includes placing stents and balloons in patients with coronary artery disease.

"The first case was very successful. Sitting away from the patient in a radiation-protected cockpit, I was able to use a joystick to advance the catheter, millimeter by millimeter through the artery," says Dr. Loyalka in a news release. "Additionally, the enhanced visualization of the technology provided me with better measurement of the blockage and placement of the stent. In my opinion, the enhanced control, visualization and measurement of this technology will transform how we perform angioplasty procedures and ultimately improve patient care."

CAD, a common but deadly disease, is the leading cause of death in America. The treatment — angioplasty procedures — remains one of the most frequently performed in the country with nearly one million cases annually, but the procedure has remained unchanged for decades.

"An aging baby boomer population is driving demand for new innovative technologies to treat CAD," continues Dr. Loyalka. "Vascular robotics offers physicians and patients a minimally-invasive technology that may improve the precision of stent and balloon placements and reduce radiation of the procedure for physicians."

The robotics technology allows interventional cardiologists to perform the procedure away from the patient's bedside and seated in a radiation-protected cockpit. The physician uses a joystick to robotically move the procedure's tools — including catheters, angioplasty balloons, and stents — to clear the blockage and restore blood flow. Additionally, the technology allows interventional cardiologists to accurately measure blockages and precisely position stents, which may lead to fewer stent implants.

"We are proud to be one of the first medical centers in the area to perform this advanced procedure," says Chris Osentowski, chief executive officer at HCA Houston Healthcare Medical Center. "It emphasizes our continuous commitment to delivering state-of-the-art technology to our patients and clinical community."

In March, HCA Houston Healthcare Clear Lake performed its first peripheral lung biopsy using robotic-assisted technology, making it the first hospital in the area to perform that procedure.

Trending News

Building Houston

 
 

BiVACOR has received fresh funding from its investors to further develop its artificial heart. Photo courtesy of BiVACOR

A Houston medical device company that is developing an artificial heart announced it has received investment funding to the tune of $18 million.

BiVACOR's investment round was led by Boston-based Cormorant Asset Management and Australia's OneVentures's Healthcare Fund III. According to the company, the funding will be deployed to continue research and development, hiring executives, and support the path to first in human trials.

“We are extremely grateful for the ongoing support from our core investors," says Thomas Vassiliades, who was named CEO of BiVACOR last year, in a news release. "This additional commitment further validates our technology and the need for improved options to treat end-stage biventricular heart failure.

“With this financing, we will be able to double the size of our organization and add key positions from the C-suite to research and development. We are well positioned to advance our preclinical activities and aim to conduct our First in Human early feasibility study planned for the end of the year,” he continues.

Billed as the first long-term treatment for patients with severe biventricular heart failure, the BiVACOR Total Artificial Heart is an implantable artificial heart that utilizes rotary blood pump technology. This technology includes magnetic levitation and is a "durable, reliable, and biocompatible heart replacement," per the company's release. It's about the size of a fist and can be used in a wide range of patients including some children and women and up to adult males.

“Under the leadership of its expert management team, the company has developed a credible strategy for growth as they march toward first in human studies,” says Jeannie Joughin, board chair and principal at One Ventures, in the release. “There is a huge gap in care for patients waiting for a heart transplant, and we are confident that BiVACOR will continue to execute its strategy to swiftly get the Total Artificial Heart into the patients who need it most.”

The company raised its $22 million series B round in early 2021, which was also led by Cormorant Asset Management and OneVentures. To date, BiVACOR has raised $60 million.

“BiVACOR continues to execute on its strategy, and there was no question that we would jump in to lead this funding,” says Bihua Chen, CEO and founder of Cormorant Asset Management. “We are impressed by BiVACOR’s world-class team and continued dedication to push the technology in the clinic. We’re excited to support their growth and vision to transform the treatment of biventricular heart failure with the world’s first fully MAGLEV total artificial heart.”

Founded in 2008, BiVACOR maintains offices in Cerritos, California, and Brisbane, Australia. The company is affiliated with Houston's Texas Heart Institute, where the world's first artificial heart was implanted. BiVACOR's headquarters is at the Texas Medical Center complex.

Trending News